Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Edward Moore

Interventional Cardiology Evansville, IN Medical Doctor

NPI 1578527263 CMS profile 25551

520 Mary St., Suite 230, Evansville, IN 47710

Open in the dashboard

General payments

$5,612

400 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Edward Moore of Evansville, IN is reported in the CMS Open Payments database as having received $5,612 across 400 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 41st percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $1,216 80
2022 General $1,186 81
2021 General $1,296 100
2020 General $452 28
2019 General $1,461 111

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Edward Moore
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Edward Moore were reported at $0. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Edward Moore Interventional Cardiology median Middle half National median
2019 $1,461 $1,097 $329–$3,048 $163
2020 $452 $473 $161–$1,480 $114
2021 $1,296 $677 $233–$1,827 $132
2022 $1,186 $978 $333–$2,724 $149
2023 $1,216 $1,136 $382–$2,986 $160
2024 $0 $1,181 $395–$3,326 $164
2025 $0 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Janssen Pharmaceuticals, Inc $954 82 payments
  2. AstraZeneca Pharmaceuticals LP $829 43 payments
  3. Novartis Pharmaceuticals Corporation $768 92 payments
  4. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $648 46 payments
  5. Amgen Inc. $371 26 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $297 16 payments
  7. E.R. Squibb & Sons, L.L.C. $287 13 payments
  8. Pfizer Inc. $283 20 payments
  9. Merck Sharp & Dohme Corporation $275 18 payments
  10. Abiomed $217 7 payments
  11. Other $684 37 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $5,514 398 payments
  2. Education $98 2 payments
Products named General payments · program years 2019–2023
  1. XARELTO $954 82 payments
  2. LifeVest $648 46 payments
  3. BRILINTA $634 34 payments
  4. ENTRESTO $422 51 payments
  5. Repatha $371 26 payments
  6. FARXIGA $321 12 payments
  7. VERQUVO $275 18 payments
  8. JARDIANCE $246 13 payments
  9. Impella $217 7 payments
  10. CAMZYOS $204 7 payments
  11. Other $1,848 148 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

235

Median for Interventional Cardiology: 2,236

Drug cost

$81,367

Median for Interventional Cardiology: $380,412

Branded share of claims

38.3%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Entresto Sacubitril/Valsartan Brand 23 $28,410
Eliquis Apixaban Brand 18 $27,254
Repatha Sureclick Evolocumab Brand 23 $23,993
Atorvastatin Calcium Generic 62 $458
Metoprolol Succinate Generic 30 $386
Isosorbide Mononitrate Er Isosorbide Mononitrate Brand 15 $241
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 11 $226
Carvedilol Generic 25 $204
Amlodipine Besylate Generic 11 $101
Furosemide Generic 17 $95

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Records

400 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record